SPRINGWORKS THERAPEUTICS INC. - COMMON STOCK

SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Nirogacestat for the Treatment of Adults with Desmoid Tumors

27 Dec 2022 05:30:07 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Participate in the Evercore ISI 5th Annual HealthCONx Conference

22 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

03 Nov 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Dosing of First Patient in Phase 2 Trial Evaluating Nirogacestat in Patients with Ovarian Granulosa Cell Tumors

29 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Data from Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Progressing Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2022

10 Sep 2022 09:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces $225 Million Private Placement Financing

07 Sep 2022 08:56:00 By Nasdaq GlobeNewswire

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma

07 Sep 2022 08:55:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022

19 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference

02 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors

15 Jul 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day

10 Jun 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

09 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting

26 May 2022 16:15:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Nirogacestat Achieved Primary and All Key Secondary Endpoints in Phase 3 DeFi Trial in Adult Patients with Progressing Desmoid Tumors

24 May 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Host Virtual R&D Day on June 10, 2022

16 May 2022 07:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 May 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Regeneron to Evaluate Nirogacestat in Combination with REGN5458 in Patients with Relapsed or Refractory Multiple Myeloma

19 Apr 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights

24 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

SpringWorks Therapeutics to Present at Upcoming Investor Conferences

01 Feb 2022 05:30:00 By Nasdaq GlobeNewswire